Monday, May 23, 2005; Page E05
Name: Alba Therapeutics
Location: Baltimore
Funding: The company raised $2 million in seed money from Astellas
Pharma, formerly Fujisawa Pharmaceutical; Esperance BioVentures; and
angel investors. Alba also received $300,000 from the Maryland
Business and Economic Development Department; $75,000 from
Maryland's Technology Development Corp.; and $70,000 from the
University of Maryland's Maryland Industrial Partnerships program.
The company is in discussions with several venture funds for a
Series A funding round.
Big idea: Alba is working on cloning a receptor for a protein called
zonulin that regulates structures in the human body known as tight
junctions. Tight junctions sit between cells, acting as barriers in
the linings of the lungs, blood vessels, skin cells and the
gastrointestinal tract. They help keep the body's fluids where they
belong. Alba is developing and commercializing drugs based on
zonulin.
How it works: "Zonulin is the garage-door opener that causes the
junctions to open," said Blake Paterson, co-founder and chief
executive. He said it can be used to deliver drugs, such as insulin
through the gut, or to block the passage of fluids containing
antigens that cause autoimmune diseases such as Type 1 diabetes,
multiple sclerosis and celiac disease, commonly known as gluten
intolerance.
"We're focusing initially on a blocker," Paterson said. "Our first
two diseases are celiac disease and Type 1 diabetes." Paterson said
Alba has been able to "shut down" Type 1 diabetes in rats by
manipulating the zonulin pathway. "We have great hopes that this
will be taken as a pill before meals to allow us to treat celiac
disease, then Type 1 diabetes."
Where the idea was hatched: Alessio Fasano, a professor at the
University of Maryland, discovered the role of zonulin. Alba
Therapeutics spun off from the university last year.
Founded: April 2004
Who's in charge: Blake M. Paterson, co-founder and chief executive;
Alessio Fasano, co-founder and chief scientific officer.
Employees: Six. Company executives anticipate "ramping up
dramatically" after they complete their Series A funding round and
hope to move to a new space in the UMB Biopark in Baltimore, which
is under construction.
Web site:
http://www.albatherapeutics.comWhat the name means: "Alba means 'the dawn' or 'the new awakening'
in Latin, Italian and Spanish," Paterson said.
Quote: "We're turning the entire science upside down," Paterson
said. "We're proposing a radical departure from the field of
autoimmunity."